Cytokinetics Earnings Estimates, EPS & Revenue | NASDAQ:CYTK

Comments

Cytokinetics Inc Earnings Estimates

CYTKNASDAQ

Trade with Public

$66.73

0.120.18%

At close: Apr 2, 5:00 PM EST

$66.00

-0.73-1.09%

After Hours: Apr 2, 4:28 PM EST

Overview NewsEarningsOptions Guidance Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Cytokinetics Earnings Estimates, EPS & Revenue | NASDAQ:CYTK

Cytokinetics (CYTK) is scheduled to report Q1 earnings on May 5, 2026. Analysts estimate EPS of $-1.64 and quarterly revenue of $8.29M.

In the most recent quarter (Q4), Cytokinetics reported EPS of $-1.50, missing estimates of $-1.41 by 0.06%. Revenue came in at $17.75M, exceeding the estimate of $6.37M by 1.79%.

Over the last 4 quarters, Cytokinetics has averaged an EPS surprise of 0.06% and a revenue surprise of 6.51%.

Earnings Date

May 5

EPS Estimate

$-1.640

Quarterly Revenue Estimate

$8.29M

Annual Revenue
(as of Dec 31)

$88.04M

Cytokinetics Earnings History

Analyze the earnings history of Cytokinetics using advanced sorting and filters.

Loading calendar...

Cytokinetics (CYTK) Earnings Per Share

The chart below shows Cytokinetics's reported EPS compared to analyst estimates over recent quarters.

Cytokinetics (CYTK) Revenue

The chart below shows Cytokinetics's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Cytokinetics (NASDAQ:CYTK) reporting earnings?

Cytokinetics (CYTK) is scheduled to report earnings on May 5, 2026. The last reported earnings were for reported on February 24, 2026 for Q4.

What were the latest earnings per share (EPS) for Cytokinetics (NASDAQ:CYTK)?

The Actual EPS was $-1.50, which missed the estimate of $-1.41.

What were Cytokinetics’s (NASDAQ:CYTK) revenues?

The Actual Revenue was $17.75M, which beat the estimate of $6.37M.

People Also Watch

Cogent Biosciences Inc

NASDAQ:COGT

$35.18

-0.09%

Neurocrine Biosciences Inc

NASDAQ:NBIX

$131.20

-0.30%

Centessa Pharmaceuticals PLC

NASDAQ:CNTA

$39.69

Ionis Pharmaceuticals Inc

Protagonist Therapeutics Inc

Cytokinetics Earnings Estimates, EPS & Revenue | NASDAQ:CYTK

Cytokinetics (CYTK) is scheduled to report Q1 earnings on May 5, 2026. Analysts estimate EPS of $-1.64 and quarterly revenue of $8.29M.

In the most recent quarter (Q4), Cytokinetics reported EPS of $-1.50, missing estimates of $-1.41 by 0.06%. Revenue came in at $17.75M, exceeding the estimate of $6.37M by 1.79%.

Over the last 4 quarters, Cytokinetics has averaged an EPS surprise of 0.06% and a revenue surprise of 6.51%.

Earnings Date

May 5

EPS Estimate

$-1.640

Quarterly Revenue Estimate

$8.29M

Annual Revenue
(as of Dec 31)

$88.04M